We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Next-Gen Products Driving Global POC Molecular Diagnostics Market

By LabMedica International staff writers
Posted on 31 Dec 2018
The global point of care (POC) molecular diagnostics market is expected to grow at a CAGR of close to 14% during the period 2019-2023, driven mainly by the growing number of M&As and collaborations, and rising focus on next-generation products.

These are the latest findings of Technavio Research, (London, UK), a global technology research and advisory company.

The growing number of M&As and collaborations is acting as a key growth driver of the global POC molecular diagnostics market. More...
Large companies have been increasingly acquiring and collaborating with specialized POC molecular diagnostic companies to expand their product portfolio. As a result, the parent companies have reduced their internal costs for product development, clinical study, and regulatory approvals.

The growing emphasis on technological advances will accelerate the growth of the global POC molecular diagnostics market. Advances in the field of information technology are providing ease of transmission by electronically recording and transferring the data captured. The shift from curative medicine to predictive, personalized, and preemptive medicine is also driving an increasing demand for POC molecular diagnostics. This shift, coupled with advances in the field of biosensors, smartphones, wearables, and lab-on-a-chip, is expected to improve the market. For instance, the lab-on-a-chip diagnostics system is formed based on the disposable, single-use, credit card sized, plastic cassette that hosts a microfluidic network for sample processing and analysis. Hence, several companies are adopting this advancement to broaden their product and service portfolios.

Based on application, the infectious diseases segment held the largest market share of more than 45% in 2018 and is expected to continue dominating the market during the forecast period. Geographically, the Americas led the global POC molecular diagnostics market in 2018 with a share of around 56%, followed by the EMEA and APAC. The Americas is expected to continue dominating the market during the forecast period.

Related Links:
Technavio Research


Gold Member
Aspiration System
VACUSAFE
Online QC Software
Acusera 24•7
Steam Sterilizer
Hi Vac II Line
HPV Molecular Test
BD Onclarity HPV Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A simple oral swab detected blood-matched inflammatory signals in children with primary ciliary dyskinesia, offering a needle-free way to monitor inflammation during routine care (Image credit: Shutterstock)

Simple Oral Swab Monitors Persistent Inflammation in Primary Ciliary Dyskinesia

Primary ciliary dyskinesia is a rare lung disease that affects about one in 7,500 to 10,000 live births worldwide. Symptoms can begin in the newborn period and progress to recurrent respiratory infections... Read more

Microbiology

view channel
Image: The study compares rapid molecular CPE diagnostics, which can return results in about one hour, with culture-based screening, which typically takes about 48 hours (Image credit: Adobe Stock)

Rapid Molecular Screening Aims to Accelerate Hospital Infection Control for CPE

Drug-resistant infections remain a critical patient-safety threat in hospitals, with carbapenemase-producing Enterobacterales (CPE) among the most urgent concerns. In England, reports of acquired carbapenemase... Read more

Pathology

view channel
Image: The VENTANA PTEN (SP218) RxDx Assay is a qualitative IHC assay for assessing PTEN protein in prostate adenocarcinoma, with staining performed using the OptiView DAB IHC Detection Kit on a BenchMark ULTRA instrument (Photo courtesy of Roche)

New Companion Diagnostic Expands Precision Medicine in Prostate Cancer

Prostate cancer is a leading cancer diagnosis in men and becomes particularly aggressive when it presents as metastatic, hormone-sensitive disease. Tumors with loss of phosphatase and tensin homolog (PTEN)... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.